April 2, 2024
(Reuters) – Four doses of Eli Lilly’s diabetes drug Mounjaro would remain in tight supply through 2024 due to soaring demand, the U.S. Food and Drug […]
April 2, 2024
The US Food and Drug Administration has approved danicopan (Voydeya, AstraZeneca) as an add-on therapy to treat extravascular hemolysis in adults receiving ravulizumab or eculizumab for […]
April 2, 2024
TOPLINE: Data from 12 studies suggest that rates of non-persistence to basal insulin treatment among people with type 2 diabetes (T2D) are 21%, 34%, and 37% […]
April 2, 2024
TOPLINE: A twice-daily dose of a proton pump inhibitor (PPI) leads to higher histologic response rates in patients with eosinophilic esophagitis (EoE) than a once-daily dose, […]
April 2, 2024
Several new clinical trials in prostate cancer have started recruiting in recent months. Maybe one of your patients could benefit from enrolling? Metastatic castration-sensitive prostate cancer. Adults […]
April 2, 2024
TOPLINE: The rates of screening for latent tuberculosis remain suboptimal among new users of biologic and targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs), with notable variations by […]
April 2, 2024
San Diego — In two different phase 2b trial extensions, oral treatment with Janus kinase (JAK) inhibitors showed improved skin clearance, according to presentations at a […]
April 2, 2024
(Reuters) -Roivant Sciences’ experimental drug to treat non-infectious uveitis helped reduce symptoms of the inflammatory eye disease in a mid-stage study, sending the biotech firm’s shares […]
April 2, 2024
Treatment decisions about the care of patients with non–small cell lung cancer (NSCLC) that has metastasized to the brain should always be made by a multidisciplinary […]
Prev page
123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436437438439440441442443444445446447448449450451452453454455456457458459460461462463464465466467468469470471472473474475476477478479480481482483484485486487
Next page